

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2022**

**Section A**

**Changed Classes/Guidelines: Changes Highlighted**

**Final Version**

**Date of issue: 17th December 2021**

<b>A10M</b>	<b>GLINIDE ANTIDIABETICS</b>	I2009
A10M1	<b>Glinide antidiabetics, plain</b>  Includes plain products containing repaglinide, nataglinide, mitiglinide, etc.	I2009
A10M3	<b>Glinide and biguanide antidiabetic combinations</b>  Includes combinations of glinide antidiabetics with biguanides.	I2009
A10M9	<b>Glinide antidiabetic combinations, other</b>  Includes combinations of glinide antidiabetics with other antidiabetics where there is no other appropriate class.	I2009
<b>A10N</b>	<b>DPP-IV INHIBITOR ANTIDIABETICS</b>	I2009
A10N1	<b>DPP-IV inhibitor antidiabetics, plain</b>  Includes plain products containing denagliptin, saxagliptin, sitagliptin, vildagliptin, etc.	I2009
A10N3	<b>DPP-IV inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of DPP-IV inhibitors with biguanides.	I2009
A10N9	<b>DPP-IV inhibitor antidiabetic combinations, other</b>  Includes combinations of DPP-IV inhibitors with other antidiabetics where there is no other appropriate class. Combinations of a DPP-IV with a glitazone and a biguanide are classified in A10N9. Combinations of a DPP-IV inhibitor with an SGLT2 inhibitor and a biguanide are classified in A10P9.	r2020
<b>A10P</b>	<b>SGLT2 INHIBITOR ANTIDIABETICS</b>	R2016
A10P1	<b>SGLT2 inhibitor antidiabetics, plain</b>  Includes plain products containing SGLT2 inhibitors, eg canagliflozin, dapagliflozin, empagliflozin, etc. <u>Products containing SGLT2 inhibitors for diabetes and also for heart failure and/or chronic kidney disease are classified here.</u>	<del>r2022</del> 16
A10P3	<b>SGLT2 inhibitor and biguanide antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with biguanides.	I2016
A10P5	<b>SGLT2 inhibitor and DPP-IV inhibitor antidiabetic combinations</b>  Includes combinations of SGLT2 inhibitors with DPP-IV inhibitors.	I2017

A10P9	<p><b>SGLT2 inhibitor antidiabetic combinations, other</b></p> <p>Includes combinations of SGLT2 inhibitors with other oral antidiabetics where there is no other appropriate class. Combinations of an SGLT2 inhibitor with a DPP-IV inhibitor and a biguanide are classified here.</p>	r2020
A10S	<p><b>GLP-1 AGONIST ANTIDIABETICS</b></p> <p>Includes glucagon-like peptide 1 receptor agonist antidiabetics, eg exenatide, liraglutide, lixisenatide. Combinations of GLP-1 agonist antidiabetics with human insulins or analogues are classified in A10C9.</p> <p>Products containing oral forms of GLP-1 agonists for diabetes are classified here.</p> <p><u>Products containing tirzepatide, a dual GIP and GLP-1 agonist, for diabetes are classified here.</u></p> <p>Products containing liraglutide for weight management only are classified in A8A.</p>	r202 <del>0</del> <sup>20</sup>
A10X	<p><b>OTHER DRUGS USED IN DIABETES</b></p>	R2010
A10X1	<p><b>Antidiabetic multitherapy combination products</b></p> <p>Includes combinations of antidiabetics with cardiovascular drugs where the aim is to treat both the diabetes and the cardiovascular condition. For example, rosiglitazone in combination with simvastatin. Also includes combinations of antidiabetics with anti-obesity drugs where the aim is to treat both the diabetes and the obesity. For example, metformin in combination with sibutramine.</p>	I2010
A10X9	<p><b>Other drugs used in diabetes</b></p> <p>Includes products used for the treatment of diabetes, as well as adjuvant therapy in the treatment and prevention of conditions associated with or developing from diabetes.</p> <p>Includes aldose reductase inhibitors (eg epalrestat, tolrestat), guar gum and glucose products specifically intended for the treatment of hypoglycaemic shock.</p> <p>Teas and other herbal extracts used as adjuvant therapy are classified here.</p>	I2010

<b>B1X</b>	<p><b>OTHER ANTITHROMBOTIC AGENTS</b></p> <p>Includes danaparoid, dermatan sulphate, activated protein C (drotrecogin alpha, activated), fondaparinux, <i>Ligustrum lucidum</i>, pentosan polysulphate sodium, poloxalkol, protein C. <u>Products containing caplacizumab for acquired thrombotic thrombocytopenic purpura are classified here.</u></p>	<p><u>r12022</u> 04</p>
------------	---	-----------------------------

<b>B2D</b>	<b>BLOOD COAGULATION <u>PRODUCTS</u></b>	<u>r2022</u>
B2D1	<b>Factor VIII, including substitutes</b>  Includes antihaemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	r2019
B2D2	<b>Factors II, VII, IX and X</b>  Includes antihaemophilic globulin B and prothrombin complex.	
B2D3	<b>Anti-inhibitor-coagulation complex</b>  Includes aPCC (activated prothrombin complex concentrate), activated FVII (FVIIa), and eptacog alfa.	R2003
B2D4	<b>Factor XIII</b>	
B2D5	<b>Fibrinogen</b>	
B2D6	<b>Fresh frozen plasma and antihaemophilic plasma</b>	
B2D7	<b>Cohn-Fraction I</b>	
B2D8	<b>Platelet concentrates</b>	
B2D9	<b>Other blood fractions</b>  Includes products containing von Willebrand factor (single ingredient).	R2005
<b>B2E</b>	<b>THROMBOPOIETIN AGONISTS</b>  Includes products containing thrombopoietin agonists, such as eltrombopag and romiplostim.  Products containing oprelvekin for the prevention of severe thrombocytopenia are classified in B6X.	r2021
<b>B2F</b>	<b>TISSUE SEALING PREPARATIONS</b>  Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	r2016

<p><b>D5</b></p>	<p><b>NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes products for psoriasis, hyperkeratosis, ichthyosis, eczema, dermatitis, seborrhoea. Psoralens are classified here when used for inflammatory conditions. Excluded from this class are combinations with antibacterials (D6A), antifungals (D1A) and products specifically indicated in acne (D10A). Sulphur baths which contain other substances besides sulphur and are not used for dermatological purposes, are classified in M2A.</p>	<p><u>r2019</u></p>
<p><b>D5A</b></p>	<p><b>TOPICAL ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products containing substances such as tar, coal tar, ichthammol, dithranol, psoralens, salicylic acid for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing corticosteroids in combination with coal tar or salicylic acid for psoriasis are classified here. These products may also be for other inflammatory skin conditions.</p> <p>Includes products consisting of coal tar or calcipotriol, alone or in combination, when indicated for psoriasis.</p>	<p>r2019</p>
<p><b>D5B</b></p>	<p><b>SYSTEMIC ANTIPSORIASIS PRODUCTS</b></p> <p>Includes products for the treatment of psoriasis. These products may also be for other inflammatory skin conditions. Products containing <b>brodalumab</b>, ixekizumab, secukinumab or ustekinumab and indicated for psoriasis and also other non-skin conditions, eg arthritis, are classified in L4C. Psoriatic arthritis is defined as a skin condition.</p> <p>Apremilast is classified here if only for psoriatic skin conditions. Products containing apremilast for multiple conditions are classified in L4X.</p>	<p>r202<del>0</del><sup>9</sup></p>
<p><b>D5X</b></p>	<p><b>OTHER NONSTEROIDAL PRODUCTS FOR INFLAMMATORY SKIN DISORDERS</b></p> <p>Includes nonsteroidal products for inflammatory skin disorders which are not indicated for psoriasis. Specific topical immunomodulators for dermatitis are classified here.</p> <p>Products containing ingenol mebutate or diclofenac gel that are indicated for actinic keratosis are classified here. Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified in L1X8. Products containing topical fluorouracil for actinic keratosis are classified in L1B.</p> <p>Products containing dupilumab for atopic dermatitis only are classified here. Products containing dupilumab for both atopic dermatitis and asthma are classified in L4C.</p>	<p>r2019</p>

<p><b>G3X</b></p>	<p><b>OTHER SEX HORMONES AND SIMILAR PRODUCTS</b></p> <p>Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p>Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p> <p><u>Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified here. Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix for cancer are classified in L2B9.</u></p>	<p>r20<del>22</del><sup>21</sup> 5</p>
-------------------	--	--

<b>H</b>	<b>SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES)</b>	
<b>H1</b>	<b>PITUITARY AND HYPOTHALAMIC HORMONES</b>	R1995
<b>H1A</b>	<b>ACTH</b>  ACTH and synthetic analogues.	
<b>H1B</b>	Out of use; can be reused.	
<b>H1C</b>	<b>HYPOTHALAMIC HORMONES</b>	R2003
<b>H1C1</b>	<b>Gonadotrophin-releasing hormones</b>  Includes eg buserelin, deslorelin, gonadorelin, goserelin, nafarelin, leuprorelin, triptorelin, when not used as cytostatics. When these substances are used as cytostatics, they are classified in L2A3. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions, are classified in L2A3.	r2020
<b>H1C2</b>	<b>Antigrowth hormones</b>  Products for acromegaly are classified here. Lanreotide, octreotide and somatostatin are classified here. Somatostatin, when used as a haemostyptic, is classified in B2G. Growth hormone antagonists, such as pegvisomant, are classified here.	r2020
<b>H1C3</b>	<b>Antigonadotrophin-releasing hormones</b>  Cetrorelix and ganirelix are classified here. <u>Products containing relugolix or elagolix (single ingredient) for uterine fibroids or endometriosis are classified here. Products containing relugolix or elagolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X. Products containing relugolix for cancer are classified in L2B9.</u>	<del>r2020</del> 03



<b>H4</b>	<b>OTHER HORMONES</b>	
<b>H4A</b>	<b>CALCITONINS</b>  This group includes all calcitonin products (pork, salmon, eel and synthetic).	
<b>H4B</b>	<b>GLUCAGON</b>	
<b>H4C</b>	<b>GROWTH HORMONES</b>  Includes products for growth conditions and also for AIDS wasting conditions. <u>Products containing anamorelin for cachexia are classified here. Products containing lonapegsomatropin are classified here.</u>	<del>r</del> 2020
<b>H4D</b>	<b>ANTIDIURETIC HORMONES</b>  This group includes argipressin, desmopressin, lypressin, ornipressin, vasopressin.	
<b>H4E</b>	<b>PARATHYROID HORMONES AND ANALOGUES</b>  Includes parathyroid hormone analogues, teriparatide.	I2008
<b>H4F</b>	<b>ANTIPARATHYROID PRODUCTS</b>  Includes products containing eg cinacalcet, doxercalciferol, falecalcitriol, maxacalcitol, paricalcitol, when they are indicated for secondary hyperparathyroidism. Products containing vitamin D or its analogues with multiple indications are classified in A11C2.	r2014
<b>H4V</b>	Out of use; can be reused from 2011.	D2008
<b>H4X</b>	<b>OTHER HORMONES AND PREPARATIONS WITH SIMILAR ACTIONS</b>  Products containing melatonin only and indicated for sleep rhythm disturbances are classified here. Prolonged-release melatonin indicated for primary insomnia is classified in N5B1. Products for insomnia that contain a sedative/hypnotic plus melatonin are classified in N5B in the appropriate subclass (N5B2, N5B4 or N5B5).	r2009

<b>J4</b>	<b>ANTIMYCOBACTERIALS</b>	R1993
<b>J4A</b>	<b>ANTITUBERCULAR PRODUCTS</b>	r2009
	Includes all specific tubercular preparations as well as streptomycin and dihydrostreptomycin. Other antibacterials such as viomycin and cycloserine which are indicated specifically for tuberculosis are included as well as rifampicin and rifamycin where they are used mostly as tuberculostatics. Where rifampicin and rifamycin are indicated for several conditions, then they are classified in J1M.	
	The definition of 'single ingredient' means that only one specific antitubercular drug is present in the product. For example, if a product contains an antitubercular substance and also pyridoxine, this is a single ingredient product and will be classified in J4A1.	
	Kits include various different tablets or forms with different ingredients. Fixed dose products contain the ingredients in one dosage form.	
J4A1	<b>Antituberculars, single ingredient</b>	I2000
J4A2	<b>Antituberculars, kits, four or more ingredients</b>	I2000
J4A3	<b>Antituberculars, kits, three ingredients</b>	I2000
J4A4	<b>Antituberculars, kits, two ingredients</b>	I2000
J4A5	<b>Antituberculars, fixed dose, four or more ingredients</b>	I2000
J4A6	<b>Antituberculars, fixed dose, three ingredients</b>	I2000
J4A7	<b>Antituberculars, fixed dose, two ingredients</b>	I2000
J4A9	<b>Antituberculars, others</b>	I2000
<b>J4B</b>	<b>DRUGS FOR THE TREATMENT OF LEPRO</b>	r2022+ 9
	Includes preparations used for the treatment of lepra (eg aldesulphone, clofazimine, dapsone). Products containing thalidomide for cancer are classified in L1KX2 and for erythema nodosum leprosum (ENL) in L4X. Products for both cancer and ENL are classified in L1KX2.	

<b>J5</b>	<b>ANTIVIRALS FOR SYSTEMIC USE</b>	R2018
<b>J5A</b>	Out of use	D1998
<b>J5B</b>	<b>ANTIVIRALS, OTHER</b>	<del>rR201</del> <u>228</u>
	Includes systemic antivirals for herpes, influenza, <u>coronavirus, other</u> viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
<u>J5B2</u>	<u>Out of use</u>	
J5B3	<b>Herpes antivirals</b>	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	<b>Influenza antivirals</b>	r202 <u>24</u>
	Includes products indicated specifically for influenza. Products containing favipiravir for influenza only are classified here. Products containing favipiravir for COVID-19 only are classified in J5B <u>65</u> . Products containing favipiravir for both influenza and COVID-19 are classified in J5B <u>65</u> .	
J5B5	<b>Respiratory antivirals, <del>excluding influenza products</del><u>other</u></b>	<del>R#202</del> <u>24</u>
	Includes products indicated specifically for <u>treatment of</u> respiratory syncytial virus (RSV) infections. <u>Products containing palivizumab for the prevention of RSV infections are classified in J6H9.</u>	
	Also includes inhalation forms of ribavirin where no indication has been specified.	
	<del>Products containing bamlanivimab, favipiravir, remdesivir, etc specifically for COVID-19 are classified here. Products containing favipiravir for influenza only are classified in J5B4. Products containing favipiravir for both influenza and COVID-19 are classified here.</del>	
	<del>Products containing levilimab for use in COVID-19 are classified in L4C.</del>	
<u>J5B6</u>	<b><u>Coronavirus antivirals</u></b>	<u>I2022</u>
	<u>Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, molnupiravir, sotrovimab, regdanvimab, remdesivir, etc, for treatment of COVID-19.</u>	
	<u>Products containing favipiravir for influenza only are classified in J5B4 (influenza</u>	

antivirals). Products containing favipiravir for both influenza and COVID-19 are classified here.

Products containing baricitinib, levilimab, tocilizumab, etc (immunosuppressants that have been used in COVID-19) are classified in L4. Dexamethasone (has been used in COVID-19) is also classified elsewhere in the appropriate hormone class.

Vaccines for coronavirus are classified in J7E6.

J5B9

**Antivirals, others**

I2008

Includes products containing lysozyme for viral infections.

<b>J6E</b>	<b>POLYVALENT IMMUNO-GLOBULINS - INTRAMUSCULAR</b>	R2006
	The action of these homologous substances is based on a wide spectrum of antibodies mainly belonging to the IgG fraction. Includes subcutaneous as well as intramuscular forms.	
<b>J6F</b>	<b>POLYVALENT IMMUNOGLOBULINS - COMBINATION MODULATION - MAINLY INTRAMUSCULAR</b>	
	These homologous immunoglobulins include: - those whose action is not exclusively based on the IgG fraction. - those which exist in combination with other substances. - those which cause a modulation of the immune response.	
<b>J6G</b>	<b>SPECIFIC IMMUNOGLOBULINS - ANTIBACTERIAL</b>	<u>r2022</u>
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. <u>Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here.</u>	
J6G1	<b>Tetanus immunoglobulin</b>	
J6G2	<b>Pertussis immunoglobulin</b>	
J6G9	<b>Other antibacterial immunoglobulins</b>	
	This group includes diphtheria, streptococci, staphylococci and pseudomonas immunoglobulins.	
<b>J6H</b>	<b>SPECIFIC IMMUNOGLOBULINS - ANTIVIRAL</b>	<u>r2022</u>
	These homologous substances (given intramuscularly or intravenously) have a certain antibody titre against a certain specified antigen. <u>Products for post-exposure prophylaxis are classified here. Products for both post-exposure prophylaxis and for treatment are classified here. Monoclonal antibodies for treatment of COVID-19 are classified in J5B6.</u>	
J6H1	<b>Mumps immunoglobulin</b>	
J6H2	<b>Measles immunoglobulin</b>	
J6H3	<b>Rubella immunoglobulin</b>	
J6H4	<b>Hepatitis immunoglobulin</b>	
J6H5	<b>Rabies immunoglobulin</b>	
J6H9	<b>Other antiviral immunoglobulins</b>	<u>r2022</u>
	This group includes varicella-zoster, tick-borne meningo-encephalitis, poliomyelitis, cytomegaly and herpes immunoglobulins. <u>Products containing</u>	

[palivizumab for the prevention of RSV infections are classified here.](#)

<b>L1G</b>	<b>MONOCLONAL ANTIBODY ANTINEOPLASTICS</b>  Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.	R2019
<b>L1G1</b>	<b>Monoclonal antibody antineoplastics, CD20</b>  Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc. <u>Products containing ofatumumab for multiple sclerosis only are classified in N7A.</u>	<del>r</del> 2022 19
<b>L1G2</b>	<b>Monoclonal antibody antineoplastics, VEGF/VEGFR</b>  Includes products containing bevacizumab, ramucirumab, etc.	I2019
<b>L1G3</b>	<b>Monoclonal antibody antineoplastics, HER-2</b>  Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc.	r2021
<b>L1G4</b>	<b>Monoclonal antibody antineoplastics, EGFR</b>  Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.	I2019
<b>L1G5</b>	<b>Monoclonal antibody antineoplastics, PD-1/PD-L1</b>  Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc.	I2019

L1H5	<p><b>Protein kinase inhibitor antineoplastics, CDK 4/6</b></p> <p>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</p>	I2019
L1H6	<p><b>Protein kinase inhibitor antineoplastics, BTK</b></p> <p>Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.</p>	I2021
L1H9	<p><b>Protein kinase inhibitor antineoplastics, other</b></p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, Pi3K, etc.</p> <p>Includes <del>apatinib</del>, axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, <u>rivoceranib (apatinib)</u>, ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p>	r202 <u>2</u> <sup>4</sup>
L1J	<p><b>PROTEASOME INHIBITOR ANTINEOPLASTICS</b></p> <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</p>	I2018
<u>L1K</u>	<p><u><b>LIDOMIDE ANTINEOPLASTICS</b></u></p> <p><u>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</u></p> <p><u>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</u></p>	<u>I2022</u>
<u>L1L</u>	<p><u><b>PARP INHIBITOR ANTINEOPLASTICS</b></u></p> <p><u>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</u></p>	<u>I2022</u>
L1X	<p><b>ALL OTHER ANTINEOPLASTICS</b></p>	R2018
L1X1	<p><b>Alternative preparations for cancer therapy</b></p> <p>Includes products derived from Viscum (mistletoe).</p>	r2018



L1X2

~~Lidomide antineoplastics~~ Out of use

~~I2019~~  
D2022

~~Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.~~

~~Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.~~

L1X3	<p><b>HDAC inhibitor antineoplastics</b></p> <p>Includes products containing HDAC inhibitors for neoplasms, eg belinostat, entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.</p>	I2018
L1X4	<p><del>PARP inhibitor antineoplastics</del> <u>Out of use</u></p> <p><del>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</del></p>	<u>D2022</u>
L1X5	<p><b>CAR T-cell therapy antineoplastics</b></p> <p>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</p>	I2019
<u>L1X6</u>	<p><u><b>Hedgehog pathway inhibitor antineoplastics</b></u></p> <p><u>Includes products containing glasdegib, sonidegib, vismodegib, etc.</u></p>	<u>I2022</u>
L1X8	<p><b>Photosensitisers for cancer therapy</b></p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing vertoporphin for macular degeneration are classified in S1P.</p>	r2019
L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p><del>Includes products containing hedgehog pathway inhibitors, eg glasdegib, sonidegib, vismodegib, etc.</del></p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p>	r202 <u>20</u>

<b>L2</b>	<b>CYTOSTATIC HORMONE THERAPY</b>	I1994
	Includes all types of hormones used primarily in the treatment of cancers, eg adrenocorticoids, progestogens, oestrogens, anti-oestrogens and androgens.	
<b>L2A</b>	<b>CYTOSTATIC HORMONES</b>	I1994
L2A1	<b>Cytostatic oestrogens</b>	I1994
L2A2	<b>Cytostatic progestogens</b>	I1994
L2A3	<b>Cytostatic gonadotrophin-releasing hormone analogues</b>	r2020
	Buserelin, deslorelin, goserelin, nafarelin, leuprorelin and triptorelin are classified here. When these substances are not used as cytostatics they are classified in H1C. Products containing gonadotrophin-releasing hormone analogues for cancer and also for other conditions are classified here.	
L2A9	<b>Other cytostatic hormones</b>	I1994
	Includes substances such as drostanolone, testolactone.	
<b>L2B</b>	<b>CYTOSTATIC HORMONE ANTAGONISTS</b>	I1994
L2B1	<b>Cytostatic anti-oestrogens</b>	R1997
	Includes substances such as tamoxifen, mepitiostane, epitiostanol, toremifene.	
L2B2	<b>Cytostatic anti-androgens</b>	I1994
	Includes substances such as flutamide, nilutamide. Cyproterone acetate (50 mg; injectable forms) is classified here.	
L2B3	<b>Cytostatic aromatase inhibitors</b>	r2019
	Includes aminoglutethamide, anastrozole, exemestane, formestane, letrozole.	
	Products containing both ribociclib and letrozole are classified in L1H5.	
L2B9	<b>Other cytostatic hormone antagonists</b>	<del>rR200</del> <u>223</u>
	Includes fulvestrant. <u>Products containing relugolix for cancer are classified here. Products containing relugolix (single ingredient) for uterine fibroids or endometriosis are classified in H1C3. Products containing relugolix in combination with oestrogens and progestogens for uterine fibroids are classified in G3X.</u>	

<p><b>L4X</b></p>	<p><b>OTHER IMMUNOSUPPRESSANTS</b></p> <p>Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p>Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p>Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p>Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p>Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in <del>L1X2</del>L1K. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1<del>KX2</del>. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p>Products containing <u>baricitinib, tofacitinib or upadacitinib (JAK inhibitors)</u> for multiple conditions are classified here. Products containing <u>baricitinib, tofacitinib or upadacitinib</u> for rheumatoid arthritis only are classified in M1C.</p> <p>Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p><del>Products containing baricitinib for multiple conditions are classified here. Products containing baricitinib for rheumatoid arthritis only are classified in M1C.</del></p> <p>Corticosteroids are not classified here.</p>	<p>r2022<del>+</del></p>
-------------------	--	--------------------------

M1C	<p><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing <u>baricitinib</u>, tofacitinib <u>or upadacitinib</u>, and indicated for rheumatoid arthritis only, are classified here. Products containing <u>baricitinib</u>, tofacitinib <u>or upadacitinib</u> for multiple conditions are classified in L4X.</p> <p>Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p><del>Products containing baricitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing baricitinib for multiple indications are classified in L4X.</del></p> <p>Psoriatic arthritis is defined as a skin condition.</p>	r2022 <sup>+</sup>
-----	--	--------------------

<b>N7</b>	<b>OTHER CNS DRUGS</b>	R1996
<b>N7A</b>	<p><b>MULTIPLE SCLEROSIS PRODUCTS</b></p> <p>Products containing alemtuzumab, dimethyl fumarate, fingolimod, glatiramer acetate, laquinimod, teriflunomide, etc, and indicated for multiple sclerosis only, are classified here.</p> <p>Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified here.</p> <p>Products containing alemtuzumab and indicated for cancer only, are classified in L1G9.</p> <p>Products containing daclizumab and indicated for multiple sclerosis and also other conditions are classified here. Products containing daclizumab for use in kidney transplantation only are classified in L4C.</p> <p>Products containing beta interferons and indicated for multiple sclerosis only are classified here. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified in L3B2.</p> <p>Products containing mitoxantrone and indicated for both cancer and multiple sclerosis are classified in L1D.</p> <p>Products containing fampridine for improvement in walking in multiple sclerosis are classified in N7X.</p> <p><u>Products containing ofatumumab for cancer are classified in L1G1.</u></p> <p>Products containing other substances, eg corticosteroids, immunosuppressants such as azathioprine, that have multiple uses, are classified elsewhere.</p>	r20 <del>22</del> <sup>24</sup> 9
<b>N7B</b>	<p><b>ANTISMOKING PRODUCTS</b></p> <p>Includes products used to stop smoking.</p>	
<b>N7C</b>	<p><b>ANTIVERTIGO PRODUCTS</b></p> <p>Includes betahistine, cinnarizine and flunarizine when indicated for vertigo and Meniere's disease.</p>	I1996
<b>N7D</b>	<b>ANTI-ALZHEIMER PRODUCTS</b>	I1998
<b>N7D1</b>	<b>Anti-Alzheimer products, cholinesterase inhibitors</b>	R2003
	Includes eg donepezil, galantamine, rivastigmine and tacrine.	
<b>N7D9</b>	<b>All other anti-Alzheimer products</b>	I1998
	Includes all other products specifically used for Alzheimer's disease.	



<b>R3</b>	<b>ANTI-ASTHMA AND COPD PRODUCTS</b>	<b><u>r2016</u></b>
	<p>This group includes all preparations indicated for bronchial asthma and chronic obstructive pulmonary disease (COPD). It consists of preparations with bronchodilatory, broncho-spasmodic or anti-asthmatic activity.</p> <p>Bronchodilators combined with expectorants or mucolytics are generally classified in R5C.</p> <p>The need to classify combination products has led to the adoption of a hierarchical system with R3A ingredients taking precedence over R3B etc. Due to the importance of specific combinations, there are some exceptions included in R3C, R3E, R3F, and R3L.</p>	
<b>R3A</b>	<b>B2-AGONISTS</b>	<b>r2016</b>
	<p>This class includes the following substances - bambuterol, bitolterol, carbuterol, clenbuterol, fenoterol, formoterol, isoetarine, isoprenaline, orciprenaline, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, tulobuterol.</p> <p>Excluded are combinations of B2-agonists with non-steroidal respiratory anti-inflammatories (R3E) and combinations of B2-agonists with corticoids (R3F) and combinations of B2-agonists with anticholinergics (with or without corticosteroids) (R3L).</p>	
R3A1	Out of use; can be reused in 2005.	D2002
R3A2	<b>B2-agonists, systemic</b>	r2016
R3A3	<b>Long-acting B2-agonists, inhalant</b>	r20 <del>22</del> <sup>24</sup> 6
	Includes formoterol, <del>and</del> salmeterol <u>and procaterol</u> . Includes liquids and capsules to be used as inhalants.	
R3A4	<b>Short-acting B2-agonists, inhalant</b>	r2016
	Includes liquids and capsules to be used as inhalants.	
<b>R3B</b>	<b>XANTHINES</b>	
	This group includes substances such as theophylline, aminophylline, diprophylline etc.	
R3B1	<b>Xanthines, inhalant</b>	
R3B2	<b>Xanthines, systemic</b>	R1993



<b>T2</b>	<b>DIAGNOSTIC TESTS</b>	I1994
<b>T2A</b>	Out of use; can be reused from 2005.	<u>D2002</u>
<b>T2B</b>	Out of use; can be reused from 2005.	D2002
<b>T2C</b>	<b>PREGNANCY AND OVULATION TESTS</b>	I2002
<b>T2D</b>	<b>DIABETES TESTS</b>	I2002
T2D1	<b>Diabetes tests, urine</b>  Includes ketone tests.	r2014
T2D2	<b>Diabetes tests, blood</b>  Includes ketone tests.	r2014
T2D9	<b>Diabetes tests, other</b>  Includes glucose tolerance tests.	I2002
<b>T2X</b>	<b>ALL OTHER DIAGNOSTIC TESTS</b>  <u>Includes tests for coronavirus.</u>	<del>I1994</del> <u>2022</u>
T2X1	<b>All other diagnostic tests, urine</b>	I2002
T2X2	<b>All other diagnostic tests, blood</b>	I2002
T2X9	<b>All other diagnostic tests</b>  Includes in vivo and in vitro tests.	I2002

V3G2	<p><b>Hyperphosphataemia products</b></p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p><b>ANTI-INFLAMMATORY ENZYMES</b></p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p><b>ALL OTHER THERAPEUTIC PRODUCTS</b></p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</p> <p><u>Products containing lonafarnib for Hutchinson-Gilford progeria syndrome or progeroid laminopathies are classified here.</u></p> <p>4<sup>th</sup> level used only in Germany and Hungary.</p>	r202 <del>2</del> <sup>4</sup>
V3X1	<p><b>Umstimmungsmittel preparations of herbal origin</b></p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p><b>Cure-all preparations</b></p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006
V3X5	<p><b>Homeopathic preparations (1)</b></p> <p>Includes single homeopathic dilutions named after the homeopathic ingredient (eg belladonna D3) and complex series. These products can have several indications or the indication is not specified.</p>	I2006

